| Online-Ressource |
Verfasst von: | Hackl, Norman J. [VerfasserIn]  |
| Bersch, Claus [VerfasserIn]  |
| Feick, Peter [VerfasserIn]  |
| Antoni, Christoph Helmer [VerfasserIn]  |
| Franke, Andreas [VerfasserIn]  |
| Singer, Manfred V. [VerfasserIn]  |
| Nakchbandi, Inaam [VerfasserIn]  |
Titel: | Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C |
Verf.angabe: | Norman J. Hackl, Claus Bersch, Peter Feick, Christoph Antoni, Andreas Franke, Manfred V. Singer & Inaam A. Nakchbandi |
Jahr: | 2010 |
Umfang: | 8 S. |
Fussnoten: | Gesehen am 28.06.2021 |
Titel Quelle: | Enthalten in: Scandinavian journal of gastroenterology |
Ort Quelle: | Abingdon : Taylor & Francis Group, 1966 |
Jahr Quelle: | 2010 |
Band/Heft Quelle: | 45(2010), 3, Seite 349-356 |
ISSN Quelle: | 1502-7708 |
Abstract: | OBJECTIVE: Hepatic stellate cells only produce fibronectin isoforms in disease states. The isoform-defining domains can be detected in the blood circulation. This study examines whether circulating levels of fibronectin isoforms show a relationship with liver fibrosis on histology in patients with chronic hepatitis C. MATERIAL AND METHODS: In a prospective study, 50 patients with chronic hepatitis C who underwent a liver biopsy were compared to 50 matched controls and 35 patients with other liver conditions. RESULTS: Circulating levels of the fibronectin isoforms were significantly higher in patients with chronic hepatitis C compared to healthy controls [oncofetal fibronectin (oFN) 2.45 +/- 0.17 versus 1.76 +/- 0.16 mg/l, P < 0.005; extra domain-A (EDA) 1.05 +/- 0.06 versus 0.86 +/- 0.06 mg/l, P < 0.05; and extra domain-B (EDB) 14.55 +/- 0.74 versus 9.31 +/- 0.58 mg/l, P < 0.001], even though total fibronectin was lower (198.9 +/- 3.5 versus 343.6 +/- 14.5 mg/l, P < 0.001). A correlation with the fibrosis score was found for both oFN (r = 0.46, P < 0.005) and EDA (r = 0.51, P < 0.001). The combination of an elevation in both markers (oFN and EDA) in the upper quartile was associated with a specificity of > 99% for predicting significant fibrosis (stages 2-4) and 95% for predicting advanced fibrosis (stages 3-4). A combination of decreased values in the lowest tertile for both markers had a specificity of 94% for excluding significant fibrosis. Based on these findings, 30% of the patients scheduled for a liver biopsy could be correctly classified as having or not having significant fibrosis. The remainder would have to proceed with a biopsy. CONCLUSION: Circulating fibronectin isoforms produced by activated stellate cells represent a viable marker for the presence of significant fibrosis or a lack thereof. |
DOI: | doi:10.3109/00365520903490606 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3109/00365520903490606 |
| DOI: https://doi.org/10.3109/00365520903490606 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Adult |
| Biomarkers |
| Biopsy, Needle |
| Case-Control Studies |
| Cross-Sectional Studies |
| Female |
| Fibronectins |
| Hepatic Stellate Cells |
| Hepatitis C, Chronic |
| Humans |
| Liver Cirrhosis |
| Male |
| Middle Aged |
| Predictive Value of Tests |
| Protein Isoforms |
K10plus-PPN: | 1761391011 |
Verknüpfungen: | → Zeitschrift |
Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C / Hackl, Norman J. [VerfasserIn]; 2010 (Online-Ressource)